ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2008144-57ometendo-6844Research ArticleСтатьиArticlesНовости мировой эндокринологииWorld endocrinology newsBerkovskayaM A

ФГУ Эндокринологический научный центр Росмедтехнологий

-DzgoevaF K

ФГУ Эндокринологический научный центр Росмедтехнологий

-20081503200851№1 (2008)4457Copyright © Berkovskaya M.A., Dzgoeva F.K., 20082008Berkovskaya M.A., Dzgoeva F.K.Berkovskaya M.A., Dzgoeva F.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6844

• Актуальность проблемы метаболического синдрома: мнение экспертов. • Хемерин - новый адипокин, ассоциированный с ожирением и метаболическим синдромом. • Инсулинорезистентность, нарушение толерантности к глюкозе и сопутствующие метаболические сдвиги у братьев женщин с синдромом поликистозных яичников. • Ухудшает ли микроциркуляторная дисфункция инсулинзависимое поглощение глюкозы мышцами? • Кардиотрофин-1 экспрессируется в жировой ткани и его уровень увеличивается при метаболическом синдроме. • Потребление магния, метаболические нарушения и воспаление. • Красное мясо в диете. • Взаимосвязь материнского и отцовского веса при рождении c развитием метаболического синдрома у их потомков: исследование между поколениями в Южной Индии. • Правда о молоке! • Терапевтическое использование ингибиторов ароматазы у мужчин. • Снижение массы тела и улучшение состояния сопутствующих заболеваний в результате применения препарата Ксеникал (орлистат): XXL-исследование в сети первичной медицинской помощи.

• Actuality of the problem of metabolic syndrome: expert opinion. • Chemerin is a novel adipokine associated with obesity and metabolic syndrome. • Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. • Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. • Cardiotrophin-1 is expressed in adipose tissue and it is UP-regulated in the metabolic syndrome. • Magnesium Intake, Metabolic Abnormalities, and Inflammation. • Red meat in the diet. • Relationships of maternal and paternal birth weights to features of the metabolic syndrome in adult offspring: an inter-generation study in South India. • The truth about milk! • Therapeutic uses of aromatase inhibitors in men. • Reduction of body weight and co-morbidities by orlistat: The XXL - Primary Health Care Trial

ReferencesBozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007 Oct;148(10):4687-94Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007 Oct;148(10):4687-94Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia. 2007 Dec;50(12):2424-32Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia. 2007 Dec;50(12):2424-32Serne EH, de Jongh RT, Eringa EC, et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204-211.Serne EH, de Jongh RT, Eringa EC, et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204-211.The microcirculation may be a target for prevention and treatment of the metabolic syndrome. Available from: http://metabolicsyndromeinstitute.net/newsletter/MSI_Newsletter/2007-11/msi.htmThe microcirculation may be a target for prevention and treatment of the metabolic syndrome. Available from: http://metabolicsyndromeinstitute.net/newsletter/MSI_Newsletter/2007-11/msi.htmNatal C, Fortuno MA, Restituto P, Colina MI, Diez J, Varo N. Cardiotrophin-1 is expressed in adipose tissue and it is up-regulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E52-60Natal C, Fortuno MA, Restituto P, Colina MI, Diez J, Varo N. Cardiotrophin-1 is expressed in adipose tissue and it is up-regulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E52-60Simona Bo. Magnesium Intake, Metabolic Abnormalities, and Inflammation. Available from: http://metabolicsyndromeinstitute.com/informations/experts-opinionSimona Bo. Magnesium Intake, Metabolic Abnormalities, and Inflammation. Available from: http://metabolicsyndromeinstitute.com/informations/experts-opinionWilliamson CS, Foster RK, Stanner SA, Buttries JL. Red meat in the diet. Nutrition Bulletin 2005; 30: 323-355.Williamson CS, Foster RK, Stanner SA, Buttries JL. Red meat in the diet. Nutrition Bulletin 2005; 30: 323-355.Veena SR, Geetha S, Leary SD, et al. Relationships of maternal and paternal birth weights to features of the metabolic syndrome in adult offspring: an inter-generation study in South India. Fall Diabetologia 2007, Vol 50; 1: 43-54Veena SR, Geetha S, Leary SD, et al. Relationships of maternal and paternal birth weights to features of the metabolic syndrome in adult offspring: an inter-generation study in South India. Fall Diabetologia 2007, Vol 50; 1: 43-54Nugent A. The truth about milk! Nutrition Bulletin 2005; 30: 307-308.Nugent A. The truth about milk! Nutrition Bulletin 2005; 30: 307-308.de Ronde W. Therapeutic uses of aromatase inhibitors in men. Current opinion in Endocrinology, Diabetes and Obesity 2007; 3(14): 235-240.de Ronde W. Therapeutic uses of aromatase inhibitors in men. Current opinion in Endocrinology, Diabetes and Obesity 2007; 3(14): 235-240.Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL - Primary Health Care Trial. Diabetes, Obesity and Metabolism. 2005;7(1):21-27. doi: 10.1111/j.1463-1326.2004.00428.xWirth A. Reduction of body weight and co-morbidities by orlistat: The XXL - Primary Health Care Trial. Diabetes, Obesity and Metabolism. 2005;7(1):21-27. doi: 10.1111/j.1463-1326.2004.00428.x

The authors declare that there are no conflicts of interest present.